Cargando…

Case Report: Neonatal Unexplained HUS Treated With Complement Inhibitor Eculizumab

Background: Hemolytic uremic syndrome (HUS) is rare in neonates. It is probably an under-recognized condition in the early postnatal period as it presents similarly to the most common perinatal asphyxia and to differentiate the two conditions is challenging. We describe the clinical presentation of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kelen, Dorottya, Chiodini, Benedetta, Godart, Valérie, Adams, Brigitte, Stordeur, Patrick, Ismaili, Khalid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930232/ https://www.ncbi.nlm.nih.gov/pubmed/33681093 http://dx.doi.org/10.3389/fped.2020.579607

Ejemplares similares

Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing
por: Benoit, Stefanie W., et al.
Publicado: (2022)

Case Report: Sustained Efficacy of Lumasiran at 18 Months in Primary Hyperoxaluria Type 1
por: Chiodini, Benedetta, et al.
Publicado: (2022)

The Struggling Odyssey of Infantile Primary Hyperoxaluria
por: Guillaume, Adrien, et al.
Publicado: (2021)

Remission of aHUS neurological damage with eculizumab
por: Ávila, Ana, et al.
Publicado: (2015)

Eculizumab and aHUS: Spotlight on Patient-Centered Care
por: Rafat, Cédric, et al.
Publicado: (2020)

Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement
por: Pape, Lars, et al.
Publicado: (2016)

Treatment of Shiga-Toxin Hus with Severe Neurologic Features with Eculizumab
por: Umscheid, Jacob H., et al.
Publicado: (2021)

Prospective Cohort Study Investigating the Safety and Efficacy of Ambulatory Treatment With Oral Cefuroxime-Axetil in Febrile Children With Urinary Tract Infection
por: Hennaut, Elise, et al.
Publicado: (2018)

Clinical Outcome of Children With Antenatally Diagnosed Hydronephrosis
por: Chiodini, Benedetta, et al.
Publicado: (2019)

Genetics and complement in atypical HUS
por: Kavanagh, David, et al.
Publicado: (2010)

Can eculizumab be discontinued in aHUS?: Case report and review of the literature
por: Sahutoglu, Tuncay, et al.
Publicado: (2016)

Use of Eculizumab During Pregnancy in Kidney Transplant Recipients With Atypical HUS
por: Cheung, Chee Kay, et al.
Publicado: (2019)

Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report
por: Lokki, A. Inkeri, et al.
Publicado: (2020)

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
por: Bouwmeester, Romy N., et al.
Publicado: (2021)

Complement activation and effect of eculizumab in scleroderma renal crisis
por: Devresse, Arnaud, et al.
Publicado: (2016)

Blockade of the Terminal Complement Cascade Using Ravulizumab in a Pediatric Patient With Anti-complement Factor H Autoantibody-Associated aHUS: A Case Report and Literature Review
por: Wu, Xiaoyan, et al.
Publicado: (2021)

Atypical HUS and Crohn’s disease—interference of intestinal disease activity with complement-blocking treatment
por: Horváth, Orsolya, et al.
Publicado: (2021)

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
por: Rathbone, John, et al.
Publicado: (2013)

Clinical Relapses of Atypical HUS on Eculizumab: Clinical Gap for Monitoring and Individualised Therapy
por: Teoh, Chia Wei, et al.
Publicado: (2018)

Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD
por: McBride, Helen J., et al.
Publicado: (2023)

aHUS caused by complement dysregulation: new therapies on the horizon
por: Waters, Aoife M., et al.
Publicado: (2010)

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
por: Wong, Edwin K.S., et al.
Publicado: (2013)

Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome
por: Ranabothu, Saritha, et al.
Publicado: (2021)

Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy
por: Gomez-Ganda, Laura, et al.
Publicado: (2021)

Case report: Eculizumab plus obinutuzumab induction in a deceased donor kidney transplant recipient with DEAP-HUS
por: Favi, Evaldo, et al.
Publicado: (2022)

Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis
por: Sadiq, Sanober, et al.
Publicado: (2023)

Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP
por: Kelen, Kata, et al.
Publicado: (2023)

Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
por: Ohanian, Maro, et al.
Publicado: (2011)

A case report of a child with sepsis induced multiorgan failure and massive complement consumption treated with a short course of Eculizumab: A case of crosstalk between coagulation and complement?
por: Galic, Slobodan, et al.
Publicado: (2019)

The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria
por: Kim, Jin Seok, et al.
Publicado: (2010)

Erratum to: aHUS caused by complement dysregulation: new therapies on the horizon
por: Waters, Aoife M., et al.
Publicado: (2012)

COVID-19 as a potential trigger of complement-mediated atypical HUS
por: El Sissy, Carine, et al.
Publicado: (2021)

Hemolytic uremic syndrome in the setting of COVID-19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature
por: Matošević, Matija, et al.
Publicado: (2023)

Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study
por: Bouwmeester, Romy N., et al.
Publicado: (2022)

Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation
por: Yerly, Patrick, et al.
Publicado: (2022)

Eculizumab treatment alters the proteometabolome beyond the inhibition of complement
por: Nelke, Christopher, et al.
Publicado: (2023)

The first case of paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome treated with complement inhibitor eculizumab in Korea
por: Kim, Hyerim, et al.
Publicado: (2017)

Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura
por: Oh, Jisu, et al.
Publicado: (2019)

Neurochemical Alterations in Sudden Unexplained Perinatal Deaths—A Review
por: Muhammad, Nazeer, et al.
Publicado: (2018)

Early-onset of ADCK4 glomerulopathy with renal failure: a case report
por: Lolin, Ksenija, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4j9utbofvrgcc4ua6q5d9kt87i